# Niclosamide and Enzalutamide in Treating Patients With Castration-Resistant, Metastatic Prostate Cancer

> **NCT02532114** · PHASE1 · COMPLETED · sponsor: **University of Washington** · enrollment: 5 (actual)

## Conditions studied

- Castration Levels of Testosterone
- Castration-Resistant Prostate Carcinoma
- Metastatic Prostate Carcinoma
- Recurrent Prostate Carcinoma
- Stage IV Prostate Adenocarcinoma

## Interventions

- **DRUG:** Enzalutamide
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Niclosamide
- **OTHER:** Pharmacological Study

## Key facts

- **NCT ID:** NCT02532114
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-31
- **Primary completion:** 2017-11-30
- **Final completion:** 2017-11-30
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2018-04-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02532114

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02532114, "Niclosamide and Enzalutamide in Treating Patients With Castration-Resistant, Metastatic Prostate Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02532114. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*